Rami Manochakian MD, FASCO Cancer Education

“When Cancer Hits the Oncologist’s Home”. On the anniversary of his passing, I share a piece I published @OncJournal on my experience as a cancer doctor, during my father-in-law’s cancer journey. He’s a great man who beat cancer by fighting the cancer. RIP theoncologist.onlinelibrary.wiley.com/doi/full/10.16…

Registration & abstracts for #NACLC25 are OPEN! Join us Dec 5–7, 2025, in Chicago. Submit abstracts by Sept 19! bit.ly/NACLC25 🎧 Hear from co‑chairs @kamarroneMD & @rarengan #LungCancerConsidered: what’s new & why you should attend. bit.ly/NACLC25Preview @ASCO…

Great presentation on Social Media use in our @IASLC Academy by @StephenVLiu ! Thanks for your contribution! Important insights! @RManochakian @LuisRaezMD @ElinardouHelena @acmoorephd

Yes, high risk factors- this is so important to patients to get picture of landscape, there's an issue of decision fatigue- almost too many options now- the cereal aisle overwhelm, but discussion of goals, priorities in terms of lifestyle needs, and outcomes- the oncologists' job…

Join us in congratulating the following members on earning the Fellows of ASCO (FASCO) distinction last quarter! We are grateful for their extraordinary volunteer service, dedication, and commitment to ASCO. Learn more about FASCO distinction: brnw.ch/21wUiVu

🚨 Big news in #lungcancer! 📢 Final OS data from FLAURA2 💊 Tagrisso + chemo ⬆️ overall survival in 1L EGFRm NSCLC vs Tagrisso alone 🔑 Statistically & clinically meaningful 🧬 Longest median PFS in class 🛡 No restriction on post-progression Rx . It will be intresting to see…

Flaura 2 (quimio + osi) también obtiene beneficio en OS. Junto con Mariposa, nuevas opciones de intensificación de tratamiento 1a L avanzado EGFRm: mayor eficiacia, pero también mayor potencial toxicidad (efectos adversos y coste). Flaura 2 pronto disponible en 🇪🇸, Mariposa 👀

‼️Press release: #FLAURA2 shows osimertinib + chemo improves OS in EGFR+ lung cancer — “statistically significant & clinically meaningful.” Combos may be in, but informed & shared decision-making stays key. Excited to review full data! @OncoAlert

The #FDA has approved sunvozertinib for patients with #EGFR exon 20 insertions, but what sets this therapy apart? On #LungCancerConsidered, @StephenVLiu, @MariamAlex26 & Dr. James Chih-Hsin Yang break down the data and explore clinical impact. 🎧 bit.ly/FDAexon20

🔥🚨HOT OFF THE PRESS Published @JCO_ASCO TWO @ASCO Living #Guideline updates Version 2025.1 by great experts on: Therapy for Stage IV Non-Small Cell #LungCancer: 1) WITHOUT Driver Alterations 👉 brnw.ch/21wUfz5 2) WITH Driver Alterations 👉 brnw.ch/21wUekt

Update to the @ASCO Living Guidelines for NSCLC without a driver alteration @JCO_ASCO from @dwightowenmd et al includes discussion on ivonescimab, the PD-1 / VEGF bispecific antibody, and the HARMONi-2 trial. Promising results but awaiting more data. ascopubs.org/doi/10.1200/JC…

🚨 Just issued! Our new living guideline update on therapy for Stage IV #NSCLC with driver alterations is here. Stay up-to-date with the latest recommendations. Read the full article: brnw.ch/21wUekt